JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS

• US 20090156513A1
• Filed: 10/28/2008
• Published: 06/18/2009
• Est. Priority Date: 03/21/2003
• Status: Active Grant

• Current Assignee: K2A LLC
• Original Assignee: K2A, Inc.
• Inventors: Schauss, Alexander G., Murdock, Kenneth A.
• Granted Patent: US 7,700,138 B2
• Time in Patent Office: Days
• US Class Current: 514/27
• CPC Class Codes: A23L 19/01 Instant products; Powders; Flakes; Granules A23L19/10 – A23L19/12 take precedence
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A61K 2236/51 Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
• CPC Class Codes: A61K 36/889 Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.

Claims

1. A method of inhibiting cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the Jucara-based dietary supplement composition comprises:

(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;

(b) an ORAC_FL value greater than about 350 micromole TE per gram total weight; and

(c) a residual water content less than about 3 weight percent of the total weight, wherein the composition quenches free radicals and reduces the damage induced by pathological free radicals;

or an effective amount of the Jucara-based dietary supplement composition comprising;

(a) a cyclooxygenase inhibition value greater than about 15 Aspirin®

mg equivalent per gram total weight; and

(b) a residual water content less than about 3 weight percent of the total weight.

2. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

3. The method of claim 1, wherein the composition is administered by a route of administration selected from the group consisting of:

oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.

4. A method of preventing or treating a disease or an injury associated with increased cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising the Jucara-based dietary supplement wherein the composition comprises:

(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;

(b) an ORAC_FL value greater than about 350 micromole TE per gram total weight; and

(c) a residual water content less than about 3 weight percent of the total weight, wherein the composition quenches free radicals and reduces the damage induced by pathological free radicals;

or an effective amount of the Jucara-based dietary supplement composition comprising;

(a) a cyclooxygenase inhibition value greater than about 15 Aspirin®

mg equivalent per gram total weight; and

(b) a residual water content less than about 3 weight percent of the total weight.

5. The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier.

6. The method of claim 4, wherein the composition is administered by a route of administration selected from the group consisting of:

oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.

7. The method of claim 4, wherein the disease or injury is selected from the group consisting of:

cancer, colon cancer, breast cancer, inflammatory bowel disease, Crohn'"'"'s disease, vascular disease, arthritis, ulcer, acute respiratory distress syndrome, ischemia-reperfusion injury, neurodegenerative disorders, autism, Parkinson'"'"'s Disease, Alzheimer'"'"'s Disease, gastrointestinal disease, tissue injury induced by inflammation, and tissue injury induced by an environmental toxin.